Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-5-4
pubmed:abstractText
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are widely used cholesterol-lowering agents that also possess anti-inflammatory activities. Cysteine-rich 61 (Cyr61) and CCL2 are potential osteolytic mediators in inflammatory bone diseases. The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. The therapeutic effect of simvastatin on rat apical periodontitis was also examined. The synthesis of Cyr61 in MG-63 was assessed by Western analysis. Expression of CCL2 was examined by an enzyme-linked immunosorbent assay. The effect of simvastatin on induced rat periapical lesion was examined radiographically and immunohistochemically. Western blot showed that TNF-alpha stimulated Cyr61 synthesis in MG-63, whereas simvastatin attenuated this effect in a dose-dependent manner. Simvastatin also reduced the levels of TNF-alpha-induced CCL2, and exogenous Cyr61 restored the inhibitory effects. Radiography and histopathology revealed that the administration of simvastatin markedly diminished the severity of induced rat periapical lesions. The numbers of Cyr61-synthesizing osteoblasts and CD-68-positive macrophages were also decreased. Simvastatin suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
D
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1878-3554
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
657-62
pubmed:meshHeading
pubmed-meshheading:19410078-Alveolar Bone Loss, pubmed-meshheading:19410078-Animals, pubmed-meshheading:19410078-Antigens, CD, pubmed-meshheading:19410078-Antigens, Differentiation, Myelomonocytic, pubmed-meshheading:19410078-Blotting, Western, pubmed-meshheading:19410078-Cell Count, pubmed-meshheading:19410078-Cell Line, pubmed-meshheading:19410078-Chemokine CCL2, pubmed-meshheading:19410078-Chemotaxis, pubmed-meshheading:19410078-Cysteine-Rich Protein 61, pubmed-meshheading:19410078-Disease Models, Animal, pubmed-meshheading:19410078-Disease Progression, pubmed-meshheading:19410078-Dose-Response Relationship, Drug, pubmed-meshheading:19410078-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:19410078-Humans, pubmed-meshheading:19410078-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:19410078-Immunohistochemistry, pubmed-meshheading:19410078-Macrophages, pubmed-meshheading:19410078-Osteoblasts, pubmed-meshheading:19410078-Periapical Periodontitis, pubmed-meshheading:19410078-Radiography, Dental, Digital, pubmed-meshheading:19410078-Rats, pubmed-meshheading:19410078-Rats, Sprague-Dawley, pubmed-meshheading:19410078-Simvastatin, pubmed-meshheading:19410078-Tumor Necrosis Factor-alpha
pubmed:year
2009
pubmed:articleTitle
Simvastatin as a novel strategy to alleviate periapical lesions.
pubmed:affiliation
School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't